Semax Dosage: Research Protocols, Safety & What the Evidence Shows

There is no FDA-approved or standardized Semax dosage in the United States. Semax is a synthetic peptide that has been studied in Russia and in small human and preclinical studies, but FDA's 2026 scientific review found no human pharmacokinetic studies for any route of administration and concluded that available clinical information was insufficient to characterize its safety profile. This means terms such as “recommended Semax dosage,” “optimal dose,” or “standard dosing protocol” should not be treated as established U.S. medical guidance.

Published studies do report specific Semax doses, especially for intranasal use. Those numbers are useful for understanding the research, but they are not interchangeable with a personal treatment plan. The sections below separate doses used in studies from claims made in commercial or wellness settings.

What Is Semax?

Semax is a heptapeptide with the amino-acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It contains the ACTH(4-7) fragment plus the Pro-Gly-Pro tripeptide and is often described as an analog of ACTH(4-10). It was developed in the former Soviet Union and is discussed in the scientific literature as a nootropic and neuroprotective peptide.

Regulatory status depends on the country. FDA notes that Semax is a registered drug in Russia and is available there as 0.1% and 1% nasal drops. In the United States, neither Semax free base nor Semax acetate is a component of an FDA-approved drug, and there is no applicable USP or National Formulary drug-substance monograph for either form.

Is There an FDA-Approved or Standard Semax Dosage?

No. A U.S. Semax dose range has not been established through an FDA approval process. In its 2026 evaluation, FDA reported that it could not identify human pharmacokinetic studies after Semax exposure by any route and found insufficient clinical information to characterize the safety of Semax free base or Semax acetate. FDA staff also concluded that the available evidence was insufficient to support effectiveness for the uses it reviewed, including cerebral ischemia, migraine, and trigeminal neuralgia. The agency's review therefore weighed against adding the substances to the 503A Bulks List.

A Semax dosing schedule found online may describe a research regimen, a Russian product label, a compounded-product practice, or an informal community protocol. None of those automatically constitutes an FDA-approved Semax dosage.

Semax Doses Used in Published Human Research

Human studies have used very different doses, populations, treatment durations, and outcomes. The published numbers below are best read as research doses rather than dosing recommendations.

Healthy Volunteer Research

In a 2018 study of resting-state brain activity, 14 healthy adults received a single 1.2 mg intranasal Semax dose and underwent functional MRI before treatment and again 5 and 20 minutes afterward. The study reported changes in the topology of the default mode network. It did not establish an optimal Semax dose for focus, memory, processing speed, or everyday cognitive performance.

Ischemic Stroke Research

A 1997 controlled study in acute hemispheric ischemic stroke reported daily doses of 12 mg for patients with moderate stroke and 18 mg for patients with severe stroke, with treatment courses lasting 5 to 10 days. The study included 30 Semax-treated patients and an 80-patient comparison group receiving conventional therapy.

A later study of 110 patients undergoing rehabilitation after ischemic stroke used 6,000 mcg per day for 10 days, repeated as two courses separated by a 20-day interval. The authors reported changes in plasma BDNF and functional outcomes. However, these regimens were studied in specific stroke populations and should not be converted into a general Semax daily dose for healthy adults.

Importantly, FDA's 2026 assessment concluded that the evidence available to the agency was insufficient to support Semax effectiveness for cerebral ischemia. Older and small studies can generate hypotheses, but they do not establish a U.S. treatment standard.

Semax Dosage for Cognitive Enhancement, Focus, and ADHD

There is no validated Semax dosage for cognitive enhancement, focus, brain fog, or ADHD. Small human studies have examined brain-network activity, but changes on functional imaging are not the same as proven improvements in attention, memory, or executive function. The 2018 healthy-volunteer study measured resting-state connectivity rather than establishing a cognitive-performance dose-response relationship.

FDA also noted in its 2026 review that Semax had been nominated for ADHD, but the agency did not evaluate that use because supporting literature was not found. As a result, searches for a “Semax ADHD dosage,” “Semax nootropic dosage,” or “Semax dosage for focus” do not map to an established clinical dose range.

Intranasal Semax vs Injectable Semax

Intranasal Semax Is the Better-Studied Human Route

Intranasal administration is the route represented in the available human literature reviewed by FDA. The agency identified intranasal use in healthy adults and in patients with several conditions, although adverse-event reporting was often limited or absent. Russia also registers Semax as nasal drops in 0.1% and 1% concentrations.

Injectable Semax Has a Larger Evidence Gap

Semax injections are marketed in some U.S. wellness and peptide settings, but that does not establish clinical equivalence to nasal dosing. FDA reported that it could not find human literature on subcutaneous Semax administration and found no human pharmacokinetic studies for any route. Therefore, claims that injectable Semax has proven higher bioavailability, a predictable dose conversion, or a superior effect are not supported by established human pharmacokinetic data.

How Does Semax Work?

The mechanism of Semax is not fully established in humans. Much of the mechanistic evidence comes from animal studies. In rats, Semax has been associated with changes in BDNF and trkB signaling in the hippocampus and with time-dependent changes in BDNF and NGF gene expression. In experimental focal cerebral ischemia, Semax also altered expression of genes related to immune and vascular processes.

These findings are biologically interesting, but they should not be translated directly into claims that a specific Semax dose “raises BDNF,” reduces inflammation, or produces neuroprotection in healthy people. The ischemia gene-expression work was performed in rats, while human studies remain much smaller and more limited.

Semax Safety, Side Effects, and Long-Term Use

The safety profile of Semax is not well enough characterized to assign reliable frequencies such as “common” or “rare” to specific side effects. FDA found that many published human references did not discuss adverse events and that the available clinical information was insufficient to characterize overall safety. The agency also found no human safety data for the proposed subcutaneous route.

In its safety review, FDA identified one FAERS report involving ocular pain and eye burning after use of 0.1% nasal drops, followed by hospitalization. A spontaneous report cannot by itself prove that Semax caused the event or establish how often it occurs. FDA also highlighted potential concerns involving immunogenicity, peptide aggregation, and peptide-related impurities, especially because product quality can vary with formulation and manufacturing.

Long-term Semax safety, pregnancy and breastfeeding safety, and clinically important drug interactions are not well established. FDA also discussed possible antithrombotic effects described in older literature and noted a theoretical concern about bleeding risk in susceptible patients or in combination with medications that increase bleeding risk.

Semax Concentration, Storage, and Product Quality

Semax concentration is often expressed as a percentage, in micrograms, or in milligrams, but these numbers are not interchangeable without knowing the exact formulation and delivery device. FDA confirmed that 0.1% and 1% nasal drops are registered in Russia, while products marketed in the United States may use different strengths and may not clearly identify whether they contain Semax free base, Semax acetate, or another derivative.

Storage and handling should also be formulation-specific. A universal rule such as “reconstituted Semax is good for 14 days” cannot be applied across products. FDA emphasized that peptide stability, pharmacological activity, and immunogenic properties can be highly sensitive to manufacturing and product-quality attributes. For the same reason, a concentration printed on a vial or spray does not establish purity, sterility, or clinical equivalence to a studied product.

Disclaimer: This website connects patients with licensed healthcare providers who can evaluate medical conditions and prescribe medications when appropriate. Some medications available through this service may be compounded drugs, which are customized formulations prepared by a pharmacy. The FDA does not conduct premarket review for compounded drugs to evaluate their safety, effectiveness, or quality. (See here: https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved). Individual results may vary, and these medications should only be used under the guidance of a qualified healthcare professional. The information in this article is for educational purposes only and should not be considered medical advice. Always consult your healthcare provider before starting any new treatment.